Article PDF
Use our pre-submission checklist
Avoid common mistakes on your manuscript.
Rights and permissions
About this article
Cite this article
TITAN-Studie: Erlotinib als gleichwertige Option in der Second-line-Therapie. Best Practice Onkologie 6, 12 (2011). https://doi.org/10.1007/BF03359803
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03359803